)
Edge20 Feb 2026
Dollar General: The Rural Retailer Playbook
How Dollar General built a small-box empire across rural America, scaling value and convenience into one of retail's most durable business models.
Corcept Therapeutics
Corcept Therapeutics (CORT) investor relations material
Corcept Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary24 Feb, 2026
Executive summary
2025 revenue reached $761.4 million, up from $675 million in 2024, with net income at $99.7 million, down from $141.2 million year-over-year, driven by increased demand in Cushing's syndrome treatments.
Full-year 2026 revenue guidance is $900–$1,000 million, driven mainly by the Cushing's syndrome business.
Significant demand surge for Cushing's syndrome medications, with a record number of new prescriptions and prescribers.
Transition to a new specialty pharmacy improved capacity and efficiency, resolving prior supply chain constraints and operational disruptions.
ROSELLA phase III trial in platinum-resistant ovarian cancer met both primary endpoints, showing a 35% reduction in risk of death and a 4.1-month median overall survival benefit.
Financial highlights
Cash and investments at year-end 2025 totaled $532.4 million, reflecting $245.9 million in stock repurchases and equity compensation.
Q4 2025 revenue was $202.1 million, up from $181.9 million in Q4 2024.
2025 saw a 61% increase in new prescriptions but only a 37% increase in tablets sold due to pharmacy vendor limitations.
AG (authorized generic) prescriptions accounted for 75% of Korlym volume at year-end 2025, expected to stabilize around 78% in 2026, with a 30% discount to WAC.
Gross margin remained high, with cost of sales at $12.98 million on $761.4 million revenue for 2025.
Outlook and guidance
2026 revenue guidance is $900–$1,000 million, with most growth expected from Cushing's syndrome products.
Oncology revenues are expected to contribute only a small portion in 2026 due to launch timing.
Cushing's syndrome business projected to reach at least $2 billion in annual revenue by decade's end.
Anticipated acceleration in growth upon relacorilant approval.
Multiple clinical trial results expected in 2026, including key oncology and metabolic studies.
New pharmacy's impact on 2026 revenue growth?
Relacorilant Cushing's syndrome NDA approval path?
How will GI tolerability impact ALS Phase 3?
Relacorilant Cushing's: FDA meeting outcomes
How will CATALYST/MOMENTUM change patient care?
Dazucorilant ALS: Pivotal trial design?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Corcept Therapeutics earnings date
Q1 20264 May, 2026
Corcept Therapeutics
Next Corcept Therapeutics earnings date
Q1 20264 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Corcept Therapeutics Incorporated is a pharmaceutical company focused on developing and commercializing therapies that modulate the effects of cortisol. The company targets endocrine disorders, cancer, and psychiatric conditions with proprietary small-molecule compounds. The company is headquartered in Menlo Park, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage